share_log

Ambrx Biopharma (NYSE:AMAM) Stock Price Up 3.6%

Ambrx Biopharma (NYSE:AMAM) Stock Price Up 3.6%

紐約證券交易所 (紐約證交所代碼:AMAM) 股價上漲 3.6%
Defense World ·  2023/01/21 02:11

Ambrx Biopharma Inc. (NYSE:AMAM – Get Rating)'s share price rose 3.6% during mid-day trading on Friday . The stock traded as high as $2.02 and last traded at $1.99. Approximately 163,413 shares traded hands during mid-day trading, a decline of 83% from the average daily volume of 964,432 shares. The stock had previously closed at $1.92.

安布爾克斯生物製藥公司（紐約證券交易所代碼：AMAM-獲得評級）的股價在周五中間交易期間上漲 3.6%。該股價高達 2.02 美元，最後交易價格為 1.99 美元。日間交易期間約有 163,413 股股份成交手，較每日平均成交量 964,432 股下跌 83%。該股票之前已收盤 1.92 美元。

Wall Street Analysts Forecast Growth

華爾街分析師預測增長

Separately, Robert W. Baird dropped their price objective on shares of Ambrx Biopharma from $8.00 to $4.00 in a research report on Wednesday, October 19th.

另外，羅伯特 ·W· 貝爾德在 10 月 19 日（星期三）的一份研究報告中，對安布爾克斯生物製藥股票的價格目標從 8.00 美元降至 4.00 美元。

Get
取得
Ambrx Biopharma
安布爾克斯生物製藥
alerts:
警報：

Ambrx Biopharma Trading Up 3.6 %

安布爾克斯生物製藥交易增長 3.6%

The stock's fifty day moving average is $1.53 and its two-hundred day moving average is $1.65.

該股票的五十天移動平均線為 1.53 美元，其 200 日移動平均線為 1.65 美元。

Institutional Investors Weigh In On Ambrx Biopharma

機構投資者權衡 Ambrx 生物製藥

Large investors have recently added to or reduced their stakes in the company. FMR LLC grew its holdings in Ambrx Biopharma by 0.8% during the 2nd quarter. FMR LLC now owns 3,857,679 shares of the company's stock valued at $10,223,000 after purchasing an additional 32,320 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Ambrx Biopharma by 91.5% during the 1st quarter. Renaissance Technologies LLC now owns 22,600 shares of the company's stock valued at $93,000 after acquiring an additional 10,800 shares during the last quarter. Finally, Royal Bank of Canada bought a new position in Ambrx Biopharma during the 3rd quarter valued at $46,000. 43.14% of the stock is owned by institutional investors and hedge funds.
大型投資者最近增加或減少了他們在公司的股份。FMR 有限責任公司在第二季度將其在安布爾克斯生物製藥的持有量增長了 0.8%。在上一季度額外購買 32,320 股股票後，金融有限責任公司現在擁有該公司股票的 3,857,679 股價值為 10,223,000 美元。文藝復興技術有限責任公司在第一季度提高了其在安布爾克斯生物製藥的股份 91.5%.文藝復興科技有限責任公司現在擁有該公司的股票 22,600 股，價值為 93,000 美元，在上個季度收購了 10,800 股。最後，加拿大皇家銀行在第三季度買入了安布爾克斯生物製藥的新倉位，價值為 46,000 美元。43.14％ 的股票由機構投資者和對沖基金擁有。

About Ambrx Biopharma

關於安布爾克斯生物製藥

(Get Rating)

(取得評分)

Ambrx Biopharma Inc, a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer.

Ambrx Bioharma Inc 是一家臨床階段生物製劑公司，利用其專有的擴展遺傳密碼技術平台發現並開發工程精密生物製劑。其主要候選產品是 ARX788，一種抗 HER2 抗體藥物結合物（ADC），該試驗在用於治療乳腺癌，胃食管結合癌和其他實體腫瘤的各種臨床試驗中進行研究，包括用於治療 HER2 陽性轉移性乳腺癌和胃癌的正在進行的 2/3 期臨床試驗。

Further Reading

進一步閱讀

  • Get a free copy of the StockNews.com research report on Ambrx Biopharma (AMAM)
  • MarketBeat Week in Review – 1/16 – 1/20
  • Does Old Dominion Show That Trucking Is Hitting The Brakes?
  • Nordstrom Puts Fear Of Markdowns Into Retail Sector
  • Exxon Mobil Stock: Within Striking Distance Of Buy Point
  • High-Dividend-Yielding BHP Sees China Driving '23 Growth
  • 獲取有關安伯克斯生物製藥（AMAM）的研究報告的免費副本
  • 市場節拍週的回顧 — 1/16 — 1/20
  • 老自治領是否顯示卡車正在擊中剎車？
  • 諾德斯特龍將對減價的恐懼放入零售業
  • 埃克森美孚股票：在買入點的醒目距離內
  • 高股息收益的必和必拓認為中國推動 23 年增長

Receive News & Ratings for Ambrx Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ambrx Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

接收 Ambrx 生物製藥日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Ambrx 生物製藥及相關公司的最新新聞和分析師評級的簡要每日摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論